According to the Washington Post the British drugmaker Glaxo-SmithKline has tentatively agreed to pay the U.S. government $3 billion to settle multiple civil and criminal investigations.
While the total settlement has not been made public the complaint about pharmaceutical companies has been marketing of drugs for conditions not approved by the FDA.